

# Accepted Manuscript

Melanoma circulating tumor cells: Benefits and challenges required for clinical application

G. Marsavela, C.A. Aya-Bonilla, M.E. Warkiani, E.S. Gray, M. Ziman



PII: S0304-3835(18)30204-0

DOI: [10.1016/j.canlet.2018.03.013](https://doi.org/10.1016/j.canlet.2018.03.013)

Reference: CAN 13803

To appear in: *Cancer Letters*

Received Date: 24 November 2017

Revised Date: 1 February 2018

Accepted Date: 9 March 2018

Please cite this article as: G. Marsavela, C.A. Aya-Bonilla, M.E. Warkiani, E.S. Gray, M. Ziman, Melanoma circulating tumor cells: Benefits and challenges required for clinical application, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.03.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Melanoma Circulating Tumor Cells: Benefits and Challenges Required for Clinical Application

G. Marsavela<sup>a</sup>, C. A. Aya-Bonilla<sup>a\*</sup>, M. E. Warkiani<sup>a,b</sup>, E. S. Gray<sup>a</sup> and M. Ziman<sup>a,c</sup>

<sup>a</sup>School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.

<sup>b</sup>School of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.

<sup>c</sup>School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Australia.

\* Corresponding author. School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, Perth, WA, 6027, Australia.

E-mail address: c.ayabonilla@ecu.edu.au (C. Aya-Bonilla)

**Keywords:** circulating tumor cells; biomarker; melanoma; cancer; liquid biopsy.

The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.

Download English Version:

<https://daneshyari.com/en/article/8434461>

Download Persian Version:

<https://daneshyari.com/article/8434461>

[Daneshyari.com](https://daneshyari.com)